How NMN Works: The Complete Guide to NAD+ Biology

What is NMN, and why does it matter for ageing?

Nicotinamide mononucleotide, or NMN, is one of the most studied molecules in modern longevity research. To understand why a small phosphorylated nucleotide attracts attention from laboratories in St. Louis, Tokyo, Sydney and increasingly in Kuala Lumpur, you have to start with a coenzyme called NAD+ - nicotinamide adenine dinucleotide.

NAD+ is not a vitamin, not a hormone, and not a drug. It is one of the oldest biochemical workhorses on the planet, present in every living cell from the bacteria in your gut to the neurons in your cortex.

Without NAD+, you cannot generate ATP from food. Without NAD+, your cells cannot repair damaged DNA efficiently. Without NAD+, the entire family of sirtuin enzymes - molecular regulators that have been called the body’s “longevity governors” - simply switch off.

The problem, and the reason NMN exists as a commercial supplement category in 2026, is that NAD+ levels fall as you age. Across several tissues, NAD+ concentrations tend to decline substantially with age (Verdin, 2015). This decline is not a curiosity. It correlates tightly with the metabolic slowdown, mitochondrial dysfunction, and chronic low-grade inflammation that define what biogerontologists call the “hallmarks of ageing.”

If you could refill the NAD+ tank, the reasoning goes, you might delay or even reverse some of these hallmarks. NMN is one of the leading candidates to do exactly that.

This guide walks you through the biology in detail. We will cover what NAD+ does, why it falls, how NMN converts to NAD+ in the body, what sirtuins and mitochondria have to do with all this, and where the science is still genuinely contested.

We will not oversell. As Rajman et al. (2018) - a critical review co-authored by David Sinclair himself - points out, much of the human evidence remains preliminary. By the end you will know enough to read a supplement label, evaluate a claim, and make an informed decision in the Malaysian market context.

NAD+: the coenzyme that runs your metabolism

Every textbook description of cellular respiration includes NAD+ somewhere on page one. When you eat rice, chicken, or a slice of pisang goreng, the carbohydrates and fats are broken down into smaller molecules that enter the mitochondria. Inside the mitochondria, the citric acid cycle and electron transport chain extract energy from these molecules - but they cannot do so without NAD+.

NAD+ accepts electrons, becomes NADH, donates those electrons to the electron transport chain, and is regenerated as NAD+ to start the cycle again. This is happening trillions of times per second across your body right now.

But NAD+ does much more than ferry electrons. It is also a substrate - a molecule that gets consumed, not just recycled - by three major enzyme families. The first is the sirtuins. The second is the PARPs (poly-ADP-ribose polymerases), which repair DNA damage. The third is CD38 and its relative CD157, NAD+-degrading enzymes that play roles in immune signalling.

Each of these consumers cleaves NAD+ as part of its catalytic cycle, releasing nicotinamide as a by-product. Cells must constantly resynthesise NAD+ to keep up.

There are three pathways to make NAD+ in human cells. The de novo pathway starts from tryptophan, the same amino acid in turkey and tempeh. The Preiss-Handler pathway starts from nicotinic acid, also known as niacin. And the salvage pathway recycles nicotinamide back into NAD+ through an intermediate - that intermediate is NMN.

The salvage pathway is by far the most active in most tissues, which is why NMN sits at such a strategic point in the network. As Imai and Guarente (2014) emphasised in their influential review, NAD+ biology is fundamentally about flux through the salvage pathway.

Why NAD+ falls with age

If NAD+ is so essential, why do levels fall? Three forces appear to be at work, and Verdin (2015) summarises them clearly. First, biosynthesis declines. The enzyme NAMPT, which converts nicotinamide back to NMN inside the cell, becomes less active in older tissues.

Second, consumption rises. CD38 expression climbs sharply with age, particularly in immune cells and adipose tissue, draining the NAD+ pool faster than it can be replenished. Third, chronic DNA damage activates PARPs, which also consume NAD+ to perform their repair function.

The net effect is an NAD+ deficit that worsens decade by decade. In a Malaysian context, this is compounded by lifestyle factors that further accelerate NAD+ loss: sedentary office work in Klang Valley high-rises, ultra-processed food, sleep disruption from shift work, and the metabolic stress of rising rates of type 2 diabetes.

Restoring NAD+ in this population is therefore not just a longevity question - it is a metabolic health question. For practical guidance on what dose is being studied and used, see our dosage guide.

Sirtuins: the longevity governors

The sirtuins are a family of seven enzymes (SIRT1 through SIRT7) found across yeast, worms, flies, mice, and humans. They were thrust into the spotlight in the early 2000s when researchers showed that overexpressing the yeast sirtuin SIR2 extended lifespan, and that mammalian sirtuins were activated by caloric restriction.

Each sirtuin sits in a different cellular compartment. SIRT1 and SIRT2 are mostly nuclear and cytoplasmic. SIRT3, SIRT4, and SIRT5 live in the mitochondria. SIRT6 and SIRT7 are nuclear, with SIRT6 specifically involved in genomic stability and SIRT7 in ribosomal RNA transcription.

What unites them is their absolute dependence on NAD+. Sirtuins are NAD+-consuming deacylases. They strip acetyl groups (and other acyl modifications) from histones and other proteins, and in doing so they cleave one molecule of NAD+ per reaction.

When NAD+ is abundant, sirtuins are active. When NAD+ is scarce, sirtuins go quiet. This is why the NAD+ decline of ageing is functionally a sirtuin decline as well, and why the NMN hypothesis matters: by raising NAD+, you may indirectly raise sirtuin activity.

SIRT1 in particular has been linked to insulin sensitivity, mitochondrial biogenesis through PGC-1α, and the regulation of inflammatory transcription factors like NF-κB. SIRT3 in mitochondria deacetylates dozens of metabolic enzymes, tuning them for efficiency. SIRT6 helps keep telomeres and DNA repair machinery functional.

The picture that emerges is of a coordinated network of regulators all running on the same fuel - NAD+ - and all dimming together as that fuel runs low (Imai and Guarente, 2014).

Mitochondria, ATP, and the energy you actually feel

The everyday symptom most people associate with ageing is fatigue. Climbing the stairs at KL Sentral feels heavier at 55 than it did at 25. The biology behind that subjective experience is largely mitochondrial. Mitochondria are the cell’s power plants, and their efficiency depends on a healthy NAD+/NADH ratio.

As NAD+ declines, the electron transport chain becomes less efficient, more electrons leak out as reactive oxygen species, and ATP output per unit of food drops. Older muscle has fewer mitochondria, and the ones that remain are less efficient.

Yoshino, Baur and Imai (2018) reviewed how NMN supplementation in animal models restores mitochondrial NAD+, improves oxidative phosphorylation, and reverses age-related metabolic dysfunction.

In humans, Liao et al. (2021) reported a dose-response improvement in aerobic capacity in amateur runners receiving NMN, suggesting that mitochondrial benefits may translate from mouse to person - though the trial was small and the effect modest. This is the kind of evidence that should inform expectations: real, but preliminary.

How NMN converts to NAD+ in the body

The pharmacology is where things get interesting and where genuine scientific disagreement begins. The textbook view is straightforward: oral NMN is absorbed from the gut, reaches the bloodstream, enters cells, and is converted to NAD+ by the enzyme NMNAT (nicotinamide mononucleotide adenylyltransferase). One phosphate group, one adenosine added, and NMN becomes NAD+. The salvage pathway delivers it directly.

The complication is the question of how NMN actually gets into cells. Most charged, phosphorylated molecules cannot cross the plasma membrane on their own. In 2019, Grozio and colleagues published a paper in Nature Metabolism claiming to have identified Slc12a8 as a dedicated NMN transporter - a protein that would shuttle NMN intact across the cell membrane. If true, this would mean NMN has a privileged uptake route that NR does not.

The Slc12a8 controversy

The Slc12a8 paper provoked rapid pushback. Charles Brenner’s laboratory, which has championed NR for years, argued that the experimental design did not rule out a much simpler explanation: that NMN is dephosphorylated to NR by extracellular CD73, that NR enters the cell through equilibrative nucleoside transporters, and that NR is then re-phosphorylated to NMN inside the cell by the enzyme NRK.

In this model, NMN does not enter cells as NMN - it enters as NR.

The debate matters because it bears on whether NMN has any pharmacological advantage over NR. Trammell et al. (2016) had earlier shown that oral NR robustly raises NAD+ in human blood, and the Brenner camp argues NMN is essentially an expensive way to deliver NR. The Sinclair and Imai camps maintain that the Slc12a8 route is real and tissue-specific.

As of 2026, replication efforts have produced mixed results, and the honest answer is that the field has not converged. For consumers, the practical implication is that both NMN and NR are reasonable NAD+ precursors. We compare them in detail in our NMN versus NR breakdown.

Oral pharmacokinetics: what we actually know

When you swallow an NMN capsule, several things happen. Some of the NMN may be hydrolysed in the gut to NR or even further to nicotinamide. Some may be absorbed intact. The relative proportions depend on dose, gut microbiome, and individual variation.

Yoshino et al. (2021), in the first placebo-controlled NMN trial in postmenopausal women with prediabetes, gave 250 mg per day for ten weeks and observed increases in muscle insulin sensitivity along with rises in NAD+ metabolites in blood. Irie et al. (2020) in Japanese men showed that single doses up to 500 mg were safe and produced dose-dependent rises in NAD+ metabolite markers. Igarashi et al. (2022) extended this to healthy older men with twelve weeks of dosing, again reporting rises in blood NAD+ and improvements in walking speed.

These trials share important limitations. Sample sizes are small (typically 20-60 participants). Durations are short (10-12 weeks). Outcomes are mostly biomarkers, not hard endpoints like cardiovascular events or mortality.

Rajman et al. (2018), writing in Cell Metabolism with David Sinclair as senior author, made this critique explicitly: animal data is promising, but human evidence remains thin and methodologically modest. Anyone reading marketing claims that promise “biological age reversal” from NMN should reread that sentence.

CD38 and the other side of the equation

Raising NAD+ is not only about supplying more precursor. It is also about losing less to consumption. CD38 is an NAD+-degrading enzyme that increases markedly with age, particularly in macrophages and adipose tissue, and it is now considered a major driver of the NAD+ decline.

Strategies that combine NMN with CD38 inhibition, whether through compounds like apigenin (found in parsley and chamomile) or through dedicated CD38 inhibitors in development, are an active research area. For now, the practical lever for a Malaysian consumer is exercise, which lowers CD38 expression in some tissues, combined with a precursor like NMN. Safety considerations for combining supplements are covered in our safety hub.

What this means for longevity, honestly

NMN is not a longevity drug. It is a precursor to a coenzyme whose decline is one of many overlapping features of ageing. The mouse evidence is encouraging - Mills et al. (2016) showed that twelve months of oral NMN in mice mitigated age-related physiological decline across muscle, eye, bone, and metabolic markers without observable toxicity.

The human evidence is consistent with mechanism but limited in scope and duration. Anyone who tells you NMN will add ten years to your life is selling something.

What NMN may reasonably do, based on current evidence, is raise NAD+ levels in tissues that have lost them, support sirtuin and mitochondrial function, and modestly improve some metabolic and physical performance markers in middle-aged and older adults. Whether this translates to longer or healthier life over decades is genuinely unknown.

Bottom line for Malaysian readers

For a Malaysian adult considering NMN, the biology is interesting but the marketplace is where most decisions are actually made. Several practical points anchor the science to local reality.

First, the National Pharmaceutical Regulatory Agency (NPRA) regulates supplements sold in Malaysia through product registration (yielding a MAL number); NMN’s status as a registrable supplement is still unsettled, and most NMN products on sale do not yet carry one, so treat a MAL number as a strong plus when present rather than something to expect. Registration is not approval of efficacy - it is confirmation that the product has been declared, and its facility inspected.

Second, if halal status matters to you, NMN itself is a synthetic molecule, but excipients, capsule shells, and flow agents may not be. Look for products with verifiable halal certification on the JAKIM directory; we cover this in our halal status guide.

Third, manage your expectations. The honest scientific position in 2026 is that NMN raises a biomarker (NAD+) that declines with age, and that this rise is associated with modest improvements in animal and short-term human studies.

It is not a substitute for the boring fundamentals - sleep, resistance training, a diet that does not centre on nasi lemak every day, and management of cardiometabolic risk factors. NMN is at best an adjunct to these, taken with eyes open about the state of the evidence.

The science of NAD+ biology is genuinely beautiful. A single coenzyme sits at the intersection of energy metabolism, gene regulation, and DNA repair, and its age-related decline ties together symptoms as varied as fatigue, insulin resistance, and cognitive slowing.

NMN gives us a tool to perturb that system. Whether it becomes a foundation of healthy ageing, a useful adjunct, or a footnote in the history of supplement science depends on the next decade of trials. Read the studies, watch the field, and decide for yourself.